Tag:

AV-299

Latest Headlines

Latest Headlines

Merck returns drug rights to AVEO

October 1, 2010
Portfolio prioritization has caused Merck to return AV-299, an anti-hepatocyte growth factor antibody drug, to AVEO Pharmaceuticals. In June the developer initiated a Phase II trial of the drug,

Related Tags

Press Releases

Featured Jobs